ACKNOWLEDGMENTS
We acknowledge and thank the participants, investigators, and laboratory members who took part in the clinical trials described herein. All studies in this report were supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), Rockville, Maryland, USA. The MAD study was also supported in part by a grant from the Bill & Melinda Gates Foundation. David Norris, PhD (Ecosse Medical Communications, Falmouth, MA USA) provided editorial services during the writing of the manuscript; these editorial services were supported by OPDC.Xiaoyan Zhang, Yongge Liu, and Jeffrey Hafkin are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Kelly Stinson is a consultant providing microbiology services to OPDC. All the other authors were investigators for the studies described in this paper, and they and/or their institutions received funding support from OPDC to conduct these studies.Supplemental material is available online only.
Supplemental material. Download 